These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1159 related items for PubMed ID: 15334157

  • 1. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 2. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 3. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
    Zeman M, Zák A, Vecka M, Romaniv S.
    Cas Lek Cesk; 2003 Aug; 142(8):500-4. PubMed ID: 14626567
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J.
    Am J Cardiol; 2005 Feb 15; 95(4):462-8. PubMed ID: 15695129
    [Abstract] [Full Text] [Related]

  • 5. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D, Velkeniers B, Duquet W, Betz W.
    Int J Cardiol; 2005 May 25; 101(2):231-5. PubMed ID: 15882669
    [Abstract] [Full Text] [Related]

  • 6. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2009 Aug 15; 104(4):548-53. PubMed ID: 19660610
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M, Bonnefous F, Debbas N, Irvine A.
    Arch Intern Med; 1994 Feb 28; 154(4):441-9. PubMed ID: 8117177
    [Abstract] [Full Text] [Related]

  • 8. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T, Tanabe K, Ishida H, Shimmura H, Ishikawa N, Goya N, Akiba T, Toma H.
    Transplant Proc; 2004 Sep 28; 36(7):2141-4. PubMed ID: 15518777
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH.
    Am J Cardiovasc Drugs; 2010 Sep 28; 10(3):175-86. PubMed ID: 20524719
    [Abstract] [Full Text] [Related]

  • 10. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K.
    Diabetes Res Clin Pract; 2004 May 28; 64(2):137-51. PubMed ID: 15063607
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M, Rohmer V, Farnier M, Issa-Sayegh M, Corda C, Sirugue I, Gerlinger C, Masseyeff-Elbaz MF.
    Diabetes Metab; 2000 May 28; 26(3):184-91. PubMed ID: 10880891
    [Abstract] [Full Text] [Related]

  • 12. Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.
    Chatley P, Badyal DK, Calton R, Khosla PP.
    Methods Find Exp Clin Pharmacol; 2007 Apr 28; 29(3):217-21. PubMed ID: 17520105
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M, Ducobu J, Bryniarski L.
    Am J Cardiol; 2010 Sep 15; 106(6):787-92. PubMed ID: 20816118
    [Abstract] [Full Text] [Related]

  • 14. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
    Zhu J, Ye P.
    Chin Med J (Engl); 2003 Jun 15; 116(6):840-3. PubMed ID: 12877791
    [Abstract] [Full Text] [Related]

  • 15. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 15; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 16. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I, Brook JG, Wolfovitz E.
    Eur J Intern Med; 2008 May 15; 19(3):203-8. PubMed ID: 18395165
    [Abstract] [Full Text] [Related]

  • 17. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 15; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L, Respondek W, Białobrzeska-Paluszkiewicz J, Grzybowska B, Jakóbisiak-Ostasz B, Stolarska I.
    Pol Merkur Lekarski; 2003 Jul 15; 15(85):42-6. PubMed ID: 14593958
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
    Maciejewski S, Hilleman D.
    Pharmacotherapy; 2008 May 15; 28(5):570-5. PubMed ID: 18447655
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Clin Ther; 2007 Jul 15; 29(7):1354-67. PubMed ID: 17825687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.